Uroplasty Inc

Uroplasty — Merger or Acquisition (March 2015)

26 slides from Uroplasty's merger presentation, Mar 10, 2015

  1. Slide 1: Creating a New Medical Device Company Positioned for Growth

    March 2015 Creating a New Medical Device Company Positioned for Growth

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of

  3. Slide 3: Additional Information and Where to Find It

    In connection with the proposed merger, Vision-Sciences has filed with the SEC a registration statement on Form S-4 that includes a joint proxy statement of Uroplasty and Vision-Sciences that also constitutes a prospectus of Vision-Sciences. The registration statement was declared effective by the S

  4. Slide 4: The Merger

    The Merger (NASDAQ: CGNT) - Merger expected to accelerate growth -- Highly complementary organizations and capabilities - - Expands innovative product offerings in urology - - Creates platform for growth in addressable $1.3 billion flexible endoscopy market -Innovative medical device company with gr

  5. Slide 5: Deal At-a-Glance

    Deal At-a-Glance Stock-for-stock deal with fixed exchange ratio of 3.6331 VSCI shares issued for every UPI shareUroplasty shareholders to own 62.5% and Vision-Sciences shareholders to own 37.5% upon completion of the merger (excluding shares issuable upon conversion of notes and warrants held by Vis

  6. Slide 6: This Combination Will…

    This Combination Will… Leverage the current capacity in Uroplasty’s 44 person U.S. sales team and 8 person International sales team; capitalize on existing relationships in urology to accelerate revenue growth of combined companyMake our sales team more relevant and more valuable to their customers

  7. Slide 7: Urology Market Dynamics

    Urology Market Dynamics Costs of practice are rising while reimbursement is flat to decliningPatient population with urologic disorders is predominantly beyond middle age (> 55 years); growth in the senior population, along with the large volume of chronic conditions, is increasing patient demand Fo

  8. Slide 8: Uroplasty at a Glance

    Company Summary Gross Margin Uroplasty at a Glance Note: 3/31 Fiscal Year End Total Revenue Founded in 1992NASDAQ: UPIHQ in Minnetonka, MNFY14 revenue: $24.6 million118 team members at 12/31/14 Product Revenue Mix

  9. Slide 9: Uroplasty: Changing Care to Change Lives

    Uroplasty, Inc. (UPI) Committed to Offering Transformative Treatment Options to Voiding Dysfunction Patients Uroplasty: Changing Care to Change Lives Urgent PC® The Only Commercially Available Non-Drug, Non-Surgical Treatment for Overactive Bladder (OAB)Simple and effectiveClinical validationAttract

  10. Slide 10: AUA/SUFU Overactive Bladder Treatment Guideline

    AUA/SUFU Overactive Bladder Treatment Guideline

  11. Slide 11: Urgent PC Adoption Drivers and 3rd Line Addressable Market

    3rd Line Treatment Addressable U.S. Market Urgent PC® Adoption DriversRapidly Aging PopulationDemand for Minimally Invasive OptionsLower Risk of Adverse Events & Shorter Recovery TimesIncreasing Awareness of OABImproved Healthcare Economics

  12. Slide 12: Fecal Incontinence Indication in U.S. CONFIDeNT Study

    Fecal Incontinence Indication in U.S. CONFIDeNT Study (United Kingdom)Physician-initiated, multi-center, double-blinded RCT of PTNS vs. sham12 weekly PTNS treatments, 30 minutes per treatment1:1 randomization, 227 patients (115 PTNS arm, 112 sham arm)Primary outcome: Proportion of patients achieving

  13. Slide 13: U.S. Fecal Incontinence Pivotal Trial Status

    U.S. Fecal Incontinence Pivotal Trial Status Patient outcomes seen in the CONFIDeNT Study differ from other published clinical data as well our own unpublished U.S. fecal incontinence (FI) pilot study results.However, additional studies will be needed to resolve differences in data before initiating

  14. Slide 14: Vision-Sciences At-a-Glance

    Company Summary Proprietary Technology Platform Vision-Sciences At-a-Glance Total Revenue Founded in 1987NASDAQ: VSCIHQ in Orangeburg, NYFY14 revenue: $17.1 million98 team members at 12/31/14 Note: 3/31 Fiscal Year End

  15. Slide 15: The EndoSheath Solution

    The EndoSheath® Solution Innovative technology ensures an “Always Ready, Always Sterile” endoscope

  16. Slide 16: The Growing Need Met by EndoSheath

    The Growing Need Met by EndoSheath® Cross-ContaminationA Significant Healthcare Issue“…at minimum, endoscope reprocessing problems… can lead to life-threatening infections.” Listed in the “Top 10” each of the last 5 years

  17. Slide 17: The Superbug

    The Superbug Nationwide Headlines“Superbug Infects Patients at UCLA” “Why is FDA dropping ball on 'superbug'?” “Lawmaker asks Congress to investigate” “Federal fiddling lets superbugs kill”FDA Issues Endoscope WarningEven the reprocessing won’t disinfect completelyAgency updating the scope risk info

  18. Slide 18: Vision-Sciences Comparative Reprocessing

    Vision-Sciences Comparative Reprocessing

  19. Slide 19: EndoSheath Value Proposition

    EndoSheath® Value Proposition “Always Ready, Always Sterile” Patented system allows for complete isolation of reusable endoscope from patient and user Enables Practices to Treat More Patients in Less Time, Creating Physician Capacity to Address the Growing Challenge of Managing Increasing Demand

  20. Slide 20: Cogentix Medical at a Glance

    Cogentix Medical at a Glance Total Revenue Product Revenue Mix Forecasting revenue of approximately $50 million for fiscal year beginning April 1, 2015 Organization 56 direct sales reps in U.S. and 8 direct sales reps intl.Focus on urology, with access to adjacent specialtiesScalable manufacturing

  21. Slide 21: Cogentix Medical: Financial Profile

    Cogentix Medical: Financial Profile Trailing twelve month (12/31) combined revenue of $43.7 million$25.9 million for Uroplasty$17.8 million for Vision-SciencesTTM revenue represents growth of 9%Accelerating future revenue growth10% to 14% revenue growth anticipated for fiscal year beginning April 1,

  22. Slide 22: Cogentix Medical: Financial Metrics

    Cogentix Medical: Financial Metrics Current combined market capitalization of $47.5 millionUPI = $26.0 millionVSCI = $21.5 millionCurrent combined enterprise value of $63.8 millionDebt = $26.5 millionCash = $10.2 millionEV = 1.5x TTM revenueEV = 1.3x projected FY16 revenueReverse stock split Joint p

  23. Slide 23: Leadership Team, Distribution Platform and Growth Strategy

    Depth & Breadth of Leadership TeamDistribution Platform44 U.S. Sales Reps – Uroplasty12 U.S. Sales Reps – Vision Sciences8 International Sales RepsDistributor RelationshipsFunctional ExpertiseSalesMarketingRegulatoryQuality Reimbursement Cogentix Medical: Growth Strategy Licensing & acquisition oppo

  24. Slide 24: Cogentix Medical: Growth Strategies

    Cogentix Medical: Growth Strategies GoalsAcquire innovative assets at attractive valuations Accelerate revenue growth to 15% for products in portfolio Reward shareholders through improved valuationMetricsAnticipated near-term revenue of ~ $50 millionAspire to $100 million of revenue within three yea

  25. Slide 25: Summary Benefits to Shareholders

    Summary Benefits to ShareholdersCreates new Medical Device company positioned for growthExpands innovative product offerings in urologyExtends platform for growth in addressable $1.3 billion flexible endoscopy marketNext StepsRecord date of February 20, 2015Proxy mailed on February 26, 2015Sharehold

  26. Slide 26: Cogentix Medical

    Cogentix Medical

Uroplasty — Merger or Acquisition (March 2015) on 6ix